Vicarious efficacy of tirzepatide in a cohabiting couple: An observational case report

Introduction: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, produces substantial weight loss and glycaemic improvement in people with and without type 2 diabetes mellitus (T2DM). Obesity pharmacotherapy may influence household behaviours and indirectly affect untreated cohabitants, but no prior report has described such an effect. Patient main concerns and findings: A cohabiting couple presented with obesity. The female partner (Patient A; no diabetes) sought weight loss therapy; the male partner (Patient B) had long-standing T2DM managed with insulin. Both partners were motivated to lose weight but had previously been unsuccessful through diet alone. Primary diagnoses interventions and outcomes: Patient A began tirzepatide through a pharmacy-supervised weight management programme (escalated to 5 mg weekly). Patient B did not receive any pharmacotherapy but lived in the same household. Over 32 weeks, Patient A lost >30 % of baseline weight. Patient B lost 13 % of baseline weight, HbA1c fell from 9.5 % to 6.1 %, and insulin requirements declined by approximately 70 %. These outcomes paralleled those reported in tirzepatide clinical trials despite absence of medication in Patient B. Conclusion: This case illustrates potential household-level or "vicarious" efficacy of anti-obesity pharmacotherapy. Environmental and behavioural changes in one partner may yield indirect metabolic benefits for untreated cohabitants. Recognition of such effects could inform patient counselling, cost-effectiveness assessments, and future research into family-based obesity care.